Advanced Search
Welcome to the Systematic
Review Data Repository
Welcome to the Systematic Review Data Repository
The Systematic Review Data Repository (SRDR) is a powerful and easy-to-use tool for the extraction and management of data for systematic review or meta-analysis. It is also an open and searchable archive of systematic reviews and their data.
New Announcement
To contribute data or comment on deposited projects, simply Register for an account.

Registered users, log in below:
Forgot Password?

Recently Completed and Deposited Reports Data

Interventions for central serous chorioretinopathy: a network meta-analysis

Public Report Complete
Statistics: 60 Studies, 1 Key Question, 1 Extraction Form,
Date Created: Apr 20, 2015 03:58PM
Description: The purpose of this form is to abstract data from reports corresponding to a study included in a systematic review.

Management of Suspected Opioid Overdose with Naloxone by Emergency Medical Services Personnel [Entered Retrospectively]

Public Report Complete
Statistics: 13 Studies, 5 Key Questions, 5 Extraction Forms,
Date Created: May 08, 2017 05:01PM
Description: Objectives. To compare different routes, doses, and dosing strategies of naloxone administration for suspected opioid overdose by emergency medical services (EMS) personnel in field settings, and to compare effects of transport to a health care facility versus nontransport following successful reversal of opioid overdose with naloxone. Methods. Four databases were searched through March 2017. Additional studies were identified from reference lists and technical experts. We included randomized controlled trials (RCTs) and cohort studies comparing different naloxone routes of administration, doses, or dosing strategies and on effects of transport or nontransport following successful reversal of opioid overdose with naloxone. Two investigators independently applied prespecified criteria to rate study quality. The strength of evidence was determined based on the overall risk of bias, consistency, directness, precision, and reporting bias. Results. Twelve studies met inclusion criteria. Three RCTs and four cohort studies compared different routes of administration. Two trials compared intranasal (IN) with intramuscular (IM) naloxone administration (strength of evidence [SOE] for all outcomes: low). While 2 mg of a higher-concentration formulation of IN naloxone (2 mg/1 mL) is similar in efficacy to 2 mg of IM naloxone, 2 mg of a lower-concentration formulation of IN naloxone (2 mg/5 mL formulation) is less effective than the same dose IM but associated with decreased risk of agitation and/or irritation. The 2 mg/5 mL formulation of IN naloxone studied in this trial is lower than concentrations used in the United States. In both trials, IN naloxone was associated with increased likelihood of rescue naloxone use. Although one RCT and two observational studies evaluated intravenous (IV) versus IN naloxone, evidence was insufficient to determine comparative benefits and harms, due to methodological limitations and poor applicability to U.S. EMS settings (SOE: insufficient). There was insufficient evidence from two observational studies to compare parenteral routes of administration (IM, IV, or subcutaneous [SQ]). No study compared outcomes of patients transported versus not transported following successful reversal of opioid overdose with naloxone. Five studies reported low rates of deaths and serious adverse events (0% to 1.25%) in patients not transported to a hospital after successful naloxone treatment, but used an uncontrolled design and had other methodological limitations (SOE: insufficient). Limitations. Few studies met inclusion criteria, all studies had methodological limitations, and no study evaluated naloxone auto-injectors or IN naloxone formulations recently approved by the US Food and Drug Administration (FDA). Conclusions. Low-strength evidence suggested that higher-concentration IN naloxone (2 mg/1 mL) is similar in efficacy to IM naloxone (2 mg), with no difference in adverse events. Research is needed on the comparative effectiveness of the FDA-approved naloxone auto-injectors (0.4 mg and 2 mg) and highly concentrated (4 mg/0.1 mL and 2 mg/0.1 mL) IN naloxone reformulation, different doses, and dosing strategies. Uncontrolled studies suggested that nontransport of patients following successful reversal of naloxone overdose might be associated with a low rate of serious harms, but patients were probably at low risk for such events, and there was insufficient evidence to determine risk of transport versus nontransport.

Treatments for Adults with Schizophrenia: A Systematic Review [Entered Retrospectively]

Public Report Complete
Statistics: 91 Studies, 4 Key Questions, 4 Extraction Forms,
Date Created: May 08, 2017 05:02PM
Description: Objectives. This systematic review (SR) provides evidence on pharmacological and psychosocial treatments for schizophrenia. Data sources. MEDLINE®, the Cochrane Library databases, PsycINFO® and included studies through February 2017. Study selection. We included studies comparing second generation antipsychotics (SGA) with each other or with a first generation antipsychotic (FGA) and studies comparing psychosocial interventions with usual care in adults with schizophrenia. Data extraction. We extracted study design, year, setting, country, sample size, eligibility criteria, population, clinical and intervention characteristics, results, and funding source. Results. We included one SR of 138 trials (N=47,189) and 24 trials (N=6,672) for SGAs versus SGAs, one SR of 111 trials (N=118,503) and five trials (N=1,055) for FGAs versus SGAs, and 13 SRs of 271 trials (N=25,050) and 27 trials (n=6,404) for psychosocial interventions. Trials were mostly fair quality and strength of evidence was low or moderate. For drug therapy, the majority of the head to head evidence was on older SGAs, with sparse data on SGAs approved in the last 10 years (asenapine, lurasidone, iloperidone, cariprazine, brexpiprazole), and recent long-acting injection [LAI] formulations of aripiprazole and paliperidone. Older SGAs were similar in measures of function, quality of life, mortality, and overall adverse events, except that risperidone LAI had better social function than quetiapine. Core illness symptoms were improved more with olanzapine and risperidone than asenapine, quetiapine, and ziprasidone and more with paliperidone than lurasidone and iloperidone; all were superior to placebo. Risperidone LAI and olanzapine had less withdrawal due to adverse events. Compared with olanzapine and risperidone, haloperidol, the most studied FGA, had similar improvement in core illness symptoms, negative symptoms, symptom response, and remission but greater incidence of adverse event outcomes. In comparison with usual care, most psychosocial interventions reviewed were more effective in improving intervention-targeted outcomes, including core illness symptoms. Various functional outcomes were improved more with assertive community care, cognitive behavioral therapy, family interventions, psychoeducation, social skills training, supported employment, and early interventions for first episode psychosis (FEP) than with usual care. Quality of life was improved more with cognitive behavioral therapy and early interventions for FEP than usual care. Relapse was reduced with family interventions, psychoeducation, illness self-management, family interventions, and early interventions for FEP. Conclusions. Most comparative evidence on pharmacotherapy relates to the older drugs, with clozapine, olanzapine, and risperidone superior on more outcomes than other SGAs. Older SGAs were similar to haloperidol on benefit outcomes but had fewer adverse event outcomes. Most psychosocial interventions improved functional outcomes, quality of life, and core illness symptoms, and several reduced relapse compared with usual care.

Fractional Exhaled Nitric Oxide Clinical Utility in Asthma Management

Public Report Complete
Statistics: 171 Studies, 1 Key Question, 1 Extraction Form,
Date Created: Aug 22, 2017 02:55PM
Description: To evaluate the clinical utility and diagnostic accuracy of fractional exhaled nitric oxide (FeNO) in people age 5 years and older with asthma; and the ability of FeNO measured at age 4 years or younger to predict a future diagnosis of asthma. PubMed ID:

The Role of Immunotherapy in the Treatment of Asthma

Public Report Complete
Statistics: 130 Studies, 4 Key Questions, 2 Extraction Forms,
Date Created: Jul 25, 2017 04:15PM
Description: To evaluate the efficacy and safety of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) in the treatment of allergic asthma

Diagnostic Accuracy of Screening Tests and Treatment of Post-Acute Coronary Syndrome (ACS) Depression: A Systematic Review

Public Report Complete
Statistics: 10 Studies, 2 Key Questions, 2 Extraction Forms,
Date Created: Jul 21, 2017 02:54PM
Description: Objective: To evaluate (1) the diagnostic accuracy of selected depression screening instruments and strategies versus a validated criterion standard in adult patients within 3 months of an acute coronary syndrome (ACS) event, and (2) the comparative safety and effectiveness of a broad range of pharmacologic and nonpharmacologic treatments for depression in adult patients who have received a criterion-based diagnosis of depression or had clinically important depressive symptoms using a validated depression scale, and who are within 3 months of an ACS event. Data Sources: We searched PubMed®, Embase®, PsycINFO®, CINAHL®, and the Cochrane Database of Systematic Reviews for English-language studies published from January 1, 2003, to April 27, 2017, that evaluated the accuracy of tools for diagnosing depression in patients after ACS or that evaluated interventions for treating post-ACS patients identified with depression. Review Methods: Two investigators individually screened each abstract and full-text article for inclusion; abstracted data; and rated quality, applicability, and strength of evidence. Where appropriate, random-effects models were used to compute summary estimates of effects.

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: